◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › E › ENTA

Enanta Pharmaceuticals Inc (ENTA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-03

Enanta Pharmaceuticals Inc (ENTA) operates in the BIOTECHNOLOGY industry and is headquartered in Watertown, United States with about 120 employees. Its market capitalization is roughly $312 million. In the fiscal year ended 2025-09-30, ENTA reported $65M in revenue and ($82M) in net income.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.

Interactive charts & full statements → Open the ENTA valuation workbench →

ENTA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30
Total Revenue	$65M	$65M	$68M	$79M	$86M	$97M	$122M	$205M	$207M	$103M	$88M	$161M	$48M	$32M	$42M	$42M	$23M
Gross Profit	$64M	$61M	$68M	$79M	$86M	$97M	$122M	$205M	$207M	$103M	$88M	$161M	$48M	$32M	$42M	$42M	$23M
Gross Margin %	98.2%	93.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($59M)	($85M)	($122M)	($137M)	($124M)	($110M)	($42M)	$37M	$88M	$25M	$31M	$124M	$19M	$9M	$21M	$25M	$7M
Operating Margin %	-90.0%	-130.7%	-179.9%	-173.2%	-143.7%	-112.9%	-34.0%	17.9%	42.8%	23.9%	34.9%	77.2%	39.8%	28.2%	51.0%	60.4%	30.5%
Net Income	($63M)	($82M)	($116M)	($134M)	($122M)	($79M)	($36M)	$46M	$72M	$18M	$22M	$79M	$34M	$10M	$21M	$23M	$8M
Net Margin %	-96.9%	-125.4%	-171.6%	-168.9%	-141.3%	-81.4%	-29.5%	22.6%	34.8%	17.2%	24.6%	49.1%	72.1%	30.0%	51.3%	55.7%	34.7%
EBITDA	($46M)	($71M)	($105M)	($123M)	($119M)	($106M)	($38M)	$40M	$91M	$27M	$33M	$125M	$19M	$9M	$22M	$27M	$8M
Earnings Per Share (EPS)	$-2.41	$-3.84	$-5.48	$-6.38	$-5.91	$-3.92	$-1.81	$2.21	$3.48	$0.91	$1.13	$4.09	$1.80	$0.98	$2.29	$1.82	$0.56
Shares Outstanding (M)	29M	21M	21M	21M	21M	20M	20M	21M	21M	19M	19M	19M	19M	10M	9M	13M	14M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ENTA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$14M	$17M	$19M	$15M	$18M	$15M	$17M	$15M
Gross Profit	$14M	$16M	$19M	$15M	$18M	$15M	$17M	$15M
Gross Margin %	100.0%	93.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($17M)	($12M)	($11M)	($18M)	($19M)	($25M)	($24M)	($30M)
Operating Margin %	-120.0%	-69.1%	-60.5%	-121.6%	-103.2%	-164.3%	-138.8%	-204.4%
Net Income	($20M)	($13M)	($12M)	($19M)	($18M)	($23M)	($22M)	($29M)
Net Margin %	-135.8%	-76.3%	-64.1%	-123.6%	-99.7%	-151.7%	-131.4%	-197.3%
EBITDA	($15M)	($9M)	($8M)	($15M)	($15M)	($21M)	($20M)	($26M)
Earnings Per Share (EPS)	$-0.67	$-0.45	$-0.42	$-0.87	$-0.86	$-1.06	$-1.05	$-1.36
Shares Outstanding (M)	29M	29M	29M	21M	21M	21M	21M	21M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ENTA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30	2010-09-30
Cash from Operations (CFO)	($35M)	($19M)	($79M)	($103M)	($85M)	($70M)	$7M	$71M	$29M	$53M	$36M	$77M	$20M	$11M	$23M	$24M	($10M)
Capital Expenditures (CapEx)	$2M	$13M	$18M	$9M	$2M	$1M	$1M	$5M	$3M	$3M	$5M	$2M	$1M	$1M	$0M	$0M	$0M
Free Cash Flow (FCF)	($37M)	($32M)	($97M)	($112M)	($87M)	($71M)	$6M	$66M	$26M	$50M	$31M	$74M	$19M	$10M	$22M	$24M	($10M)
FCF Margin %	-56.6%	-49.2%	-143.0%	-141.7%	-100.9%	-72.9%	4.6%	32.2%	12.7%	48.8%	35.2%	46.2%	40.1%	31.3%	53.6%	56.3%	-44.9%
Dividends Paid	—	—	—	—	—	—	—	$3M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ENTA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($10M)	($7M)	($12M)	($6M)	$18M	($13M)	($17M)	($10M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$1M	$0M	$3M	$9M	$9M
Free Cash Flow (FCF)	($10M)	($7M)	($12M)	($8M)	$17M	($16M)	($26M)	($19M)
FCF Margin %	-69.5%	-41.8%	-63.6%	-52.5%	94.7%	-107.4%	-150.6%	-132.5%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ENTA Balance Sheet History

Balance sheet	2026-06-30	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30	2015-09-30	2014-09-30	2013-09-30	2012-09-30	2011-09-30
Total Assets	$297M	$281M	$377M	$462M	$381M	$441M	$491M	$490M	$414M	$327M	$281M	$246M	$155M	$117M	$52M	$26M
Cash & Cash Equivalents	$33M	$32M	$37M	$85M	$44M	$57M	$87M	$51M	$64M	$66M	$17M	$22M	$31M	$9M	$11M	$7M
Total Liabilities	$196M	$216M	$248M	$246M	$59M	$41M	$35M	$27M	$21M	$25M	$11M	$10M	$7M	$7M	$8M	$158M
Total Debt (Short + Long-Term)	$4M	$34M	$36M	$5M	$3M	$4M	$4M	$2M	$2M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$101M	$65M	$129M	$217M	$321M	$399M	$456M	$462M	$394M	$302M	$270M	$236M	$149M	$110M	$44M	($132M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ENTA viewer.

Other Companies in BIOTECHNOLOGY

KYTX · Kyverna Therapeutics, Inc. Common Stock — $351 million
SPRY · ARS Pharmaceuticals, Inc — $336 million
AVIR · Atea Pharmaceuticals Inc — $330 million
ARCT · Arcturus Therapeutics Holdings Inc — $314 million
PRLD · Prelude Therapeutics Inc — $309 million
BNTC · Benitec Biopharma Inc. — $305 million
VOGX · Vogenx Inc Common Stock — $301 million
SCTX · Scribe Therapeutics Inc. Common Stock — $292 million

← ENT All “E” companies ENTERO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.